Please assess the completion status of the following clinical trial:

Trial Title: Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Willing and able to provide written informed consent.~2. Male or female \>18 years of age~3. Serum HCV RNA levels of \>1,000 IU per milliliter or higher~4. HCV treatment experienced or naïve.~   * HCV treatment naïve: No prior exposure to any Interferon, ribavirin, or other approved or experimental HCV-specific directly acting antivirals~  * HCV Treatment-Experienced: Virologic failure after treatment with Pegylated interferon + ribavirin, Non-structural 3/4a (NS3/4A) protease inhibitor plus pegylated interferon + ribavirin, or regimen of sofosbuvir±ribavirin± pegylated interferon regimen.~5. Chronic Hepatitis C based on the judgment of the investigator~6. HCV genotype 1, 2, 3, 4~7. If the patient is determined to be cirrhotic (based on criteria outlined earlier), the patient must have an ultrasound done within 6 months prior to enrollment with no evidence of hepatocellular carcinoma.~8. Indolent Non-Hodgkin's lymphoma , which may include the following :~   * Nodal Marginal zone lymphoma~  * Extranodal marginal zone lymphoma (MALT)~  * Splenic marginal zone lymphoma~  * Follicular lymphoma Grade 1-3a with low tumor burden\*, FLIPI 2 risk category of either low (i.e. no risk factors) or intermediate (1-2 risk factors), and with no B symptoms. B symptoms are defined as:~     * Fever (i.e., temperature \>38°C \[\>100.4°F\]) for 3 consecutive days~    * Weight loss exceeding 10% of body weight in 6 months~    * Drenching night sweats~  * Lymphoplasmacytic lymphoma~9. No prior chemotherapy~   * Low tumor burden is defined as normal lactate dehydrogenase, largest nodal or extranodal mass less than 7 cm, up to three nodal sites containing nodes with a diameter greater than 3 cm, no clinically significant serous effusions detectable by physical examination or positron emission tomography (PET)/CT scan, and spleen enlargement up to 16 cm by CT without any evidence of portal hypertension.~10. Karnofsky performance status \> 70%~11. Creatinine clearance ≥60 mL/min, as calculated by Cockcroft-Gault equation~12. If patient will need ribavirin in their regimen then the following inclusion:~    * Hg \>12 g/dL for male~   * Hg \>11 g/dL for female~13. All women of child-bearing potential who take ribavirin will need to have a negative urine pregnancy test.~Exclusion Criteria:~1. Life expectancy \< 6 months~2. Any HCV treatment which uses pegylated interferon~3. HCV genotype 3 Treatment experienced with cirrhosis~4. Co-infection with hepatitis B~5. Prior chemotherapy for lymphoma~6. Lymphomas of other histologies other than the ones listed in section 3.3 above~7. Follicular lymphoma with large cell transformation~8. Decompensated liver disease in which pegylated interferon is contraindicated.~9. Female who is pregnant or breast feeding and HCV treatment requires use of ribavirin.~10. Solid organ transplant~11. Any interferon- containing agent within 8 weeks prior to screening or any prior exposure to HCV-specific antivirals agent(s), other than NS3/ 4A protease inhibitor and sofosbuvir~12. Known hypersensitivity to ledipasvir, sofosbuvir, or formulation excipients.~13. On a prohibited medication which cannot be stopped during the duration of HCV treatment.~14. Female subject who is pregnant or breastfeeding~15. HIV-infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- sofosbuvir/ledipasvir (Type: EXPERIMENTAL): sofosbuvir and ledipasvir fixed dose combination given orally once a day for genotype 1 and 4.
- sofosbuvir and ribavirin (Type: EXPERIMENTAL): Sofosbuvir 400 mg given orally once a day with weight-base ribavirin of 1200 mg for those \>75 kg and 1000 mg for those \<75kg given in divided dose twice a day. This intervention is for genotype 2 and 3

Based on this trial design, predict the completion outcome and termination type (if applicable).